BeOne Medicines (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Tevimbra for treating adults with resectable non-small cell lung cancer at high risk of recurrence.
The recommendation covers Tevimbra for use with chemotherapy as neoadjuvant treatment and continued as monotherapy as adjuvant treatment.
The drugmaker said the recommendation was based on a phase 3 trial, where the treatment met key goals of event-free survival and major pathologic response at the interim analyses.
Shares of the company were up 2.6% in Monday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。